Recombinant Human TAFA2/FAM19A2 Protein, CF

Recombinant Human TAFA2/FAM19A2 Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: TAFA2/FAM19A2

TAFA2 (also FAM19A2) is a secreted, 11 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 131 amino acid (aa) precursor that contains a 30 aa signal sequence and a 101 aa mature chain (SwissProt #: Q8N3H0). Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX₇CCX₁₃CXCX₁₄CX₁₁CX₄CX₅CX₁₀C, where C represents a conserved cysteine residue and X represents any noncysteine amino acid (1). Human TAFA2 is 97% aa identical to mouse TAFA2 (1). TAFA2 expression can be detected in the central nervous system (CNS), colon, heart, lung, spleen, kidney, and thymus, but its expression in the CNS is 50- to 1000-fold higher than in other tissues (1). Within the CNS, TAFA2 expression is highest in the occipital and frontal cortex (3- to 10-fold more abundantly expressed than in other cortical regions) and medulla (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1 - 2). Finally, TAFAs may control axonal sprouting following brain injury (1).